{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-25-000935","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2025-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.631214+00:00","generated_at":"2026-05-18T09:25:17.694129+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Anavex extends CEO Missling's term to 2028 with $800k salary; PFO receives indefinite term and increased severance","bullets":["CEO Christopher Missling's employment term extended through July 5, 2028, with base salary $800,000 and target cash bonus of 20% of salary.","PFO Sandra Boenisch's employment made indefinite; base salary set at CAD $279,840 with 20% target bonus.","Boenisch's severance upon termination without cause increased from 6 to 12 months of base salary.","Both amendments effective July 3, 2025; Missling's annual equity grant remains at Compensation Committee's discretion."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-25-000935","json":"https://secwatch.observer/filing/0001731122-25-000935.json","markdown":"https://secwatch.observer/filing/0001731122-25-000935.md","text":"https://secwatch.observer/filing/0001731122-25-000935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000935/0001731122-25-000935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112225000935/e6684_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:25:17.694129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}